-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest
ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest
ChromaDex Co. (NASDAQ:CDXC – Get Rating) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,260,000 shares, an increase of 5.6% from the August 15th total of 2,140,000 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 461,600 shares, the short-interest ratio is presently 4.9 days.
Analysts Set New Price Targets
Several analysts have recently weighed in on CDXC shares. B. Riley downgraded shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.40 in a report on Thursday, August 11th. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. Finally, Oppenheimer cut shares of ChromaDex from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $5.48.
Get ChromaDex alerts:Institutional Investors Weigh In On ChromaDex
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in ChromaDex by 9.5% in the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company's stock valued at $6,842,000 after purchasing an additional 240,414 shares during the period. Tieton Capital Management LLC grew its holdings in ChromaDex by 59.9% in the second quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. State Street Corp grew its holdings in ChromaDex by 4.1% in the first quarter. State Street Corp now owns 932,526 shares of the company's stock valued at $2,294,000 after purchasing an additional 36,308 shares during the period. Millennium Management LLC purchased a new stake in ChromaDex in the second quarter valued at approximately $1,275,000. Finally, Renaissance Technologies LLC grew its holdings in ChromaDex by 76.0% in the second quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. 41.83% of the stock is currently owned by hedge funds and other institutional investors.
ChromaDex Price Performance
CDXC traded down $0.02 during midday trading on Wednesday, reaching $1.39. 200 shares of the company's stock were exchanged, compared to its average volume of 156,641. The business's 50-day moving average price is $1.64 and its 200 day moving average price is $1.90. The stock has a market capitalization of $94.99 million, a PE ratio of -3.44 and a beta of 1.74. ChromaDex has a 1-year low of $1.36 and a 1-year high of $6.98.ChromaDex (NASDAQ:CDXC – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) earnings per share. As a group, analysts expect that ChromaDex will post -0.3 EPS for the current fiscal year.
About ChromaDex
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- General Mills: Superior Returns With Less Volatility
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
ChromaDex Co. (NASDAQ:CDXC – Get Rating) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,260,000 shares, an increase of 5.6% from the August 15th total of 2,140,000 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 461,600 shares, the short-interest ratio is presently 4.9 days.
ChromaDex Co.(納斯達克:CDXC-GET Rating)是空頭股數8月份大幅上調的目標。截至8月31日,空頭股數共有226萬股,比8月15日的214萬股增加了5.6%。目前,該公司5.9%的股份被賣空。以46.16萬股的平均成交量計算,目前短息比為4.9天。
Analysts Set New Price Targets
分析師設定新的價格目標
Several analysts have recently weighed in on CDXC shares. B. Riley downgraded shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.40 in a report on Thursday, August 11th. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. Finally, Oppenheimer cut shares of ChromaDex from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $5.48.
幾位分析師最近紛紛買入CDXC的股票。B.萊利在8月11日週四的一份報告中將ChromaDex的股票評級從買入下調至中性,並將該公司的目標價從6.00美元下調至2.40美元。在8月29日週一的一份報告中,HC Wainwright將ChromaDex的股票目標價從7.00美元下調至5.50美元,並將該股的評級定為“買入”。最後,在8月16日星期二的一份研究報告中,奧本海默將ChromaDex的股票評級從“跑贏大盤”下調至“市場表現”。三位研究分析師對該股的評級為持有,兩位分析師對該公司股票的評級為買入。根據MarketBeat,該公司平均評級為持有,平均目標價為5.48美元。
Institutional Investors Weigh In On ChromaDex
機構投資者買入ChromaDex
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in ChromaDex by 9.5% in the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company's stock valued at $6,842,000 after purchasing an additional 240,414 shares during the period. Tieton Capital Management LLC grew its holdings in ChromaDex by 59.9% in the second quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. State Street Corp grew its holdings in ChromaDex by 4.1% in the first quarter. State Street Corp now owns 932,526 shares of the company's stock valued at $2,294,000 after purchasing an additional 36,308 shares during the period. Millennium Management LLC purchased a new stake in ChromaDex in the second quarter valued at approximately $1,275,000. Finally, Renaissance Technologies LLC grew its holdings in ChromaDex by 76.0% in the second quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. 41.83% of the stock is currently owned by hedge funds and other institutional investors.
一些機構投資者最近買賣了該股的股票。先鋒集團第一季度增持ChromaDex 9.5%的股份。先鋒集團目前持有該公司2,781,437股股票,價值6,842,000美元,在此期間又購買了240,414股。Tieton Capital Management LLC在第二季度增持了59.9%的ChromaDex股份。Tieton Capital Management LLC在此期間額外購買了856,273股,目前擁有2,285,015股該公司股票,價值3,816,000美元。道富集團第一季度持有的ChromaDex股份增加了4.1%。道富銀行目前持有該公司932,526股股票,價值2,294,000美元,在此期間又購買了36,308股。Millennium Management LLC在第二季度購買了ChromaDex的新股份,價值約1,275,000美元。最後,復興科技有限責任公司在第二季度增持了76.0%的ChromaDex。復興科技有限責任公司在此期間又購買了319,399股,現在擁有739,900股該公司的股票,價值1,236,000美元。41.83%的股票目前由對衝基金和其他機構投資者持有。
ChromaDex Price Performance
ChromaDex性價比
ChromaDex (NASDAQ:CDXC – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) earnings per share. As a group, analysts expect that ChromaDex will post -0.3 EPS for the current fiscal year.
ChromaDex(納斯達克代碼:CDXC-GET Rating)上一次公佈季度收益數據是在8月10日星期三。該公司公佈本季度每股收益為0.09美元,低於分析師普遍預期的0.08美元和0.01美元。ChromaDex的淨利潤率為負41.01%,股本回報率為負99.51%。去年同一季度,該業務公佈的每股收益為0.08美元。作為一個整體,分析師預計ChromaDex本財年的每股收益將達到0.3歐元。
About ChromaDex
關於ChromaDex
(Get Rating)
(獲取評級)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex公司是一家專注於健康老齡化的生物科學公司。該公司通過三個部門運營:消費品;配料;以及分析參考標準和服務。它研究煙酰胺腺嘌呤二核苷酸(NAD+);直接向消費者和經銷商提供含有其專利成分的成品膳食補充劑產品;開發基於專利的成分技術並將其商業化,並將這些成分作為原材料供應給消費品製造商。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- General Mills: Superior Returns With Less Volatility
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- 免費獲取StockNews.com在ChromaDex(CDXC)上的研究報告
- 連續60年提高股息的3只防御性股票
- 通用磨坊:波動性更小、回報更高
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但並未出局
- 如果你渴望價值,那就嚐嚐露絲的好客之道吧
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChromaDex Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ChromaDex和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧